Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
13.38
-0.40 (-2.90%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Company Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases.
It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics, Inc.
Country | United States |
Founded | 2019 |
IPO Date | Feb 10, 2023 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 28 |
CEO | Jon Congleton |
Contact Details
Address: 150 N. Radnor Chester Rd., Suite F200 Radnor, Pennsylvania 19087 United States | |
Phone | 888 378 6240 |
Website | mineralystx.com |
Stock Details
Ticker Symbol | MLYS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $16.00 |
CIK Code | 0001933414 |
CUSIP Number | 603170101 |
ISIN Number | US6031701013 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Jon Congleton | Chief Executive Officer and Director |
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder and Executive Chairman |
Adam Scott Levy | Chief Financial Officer and Secretary |
Dr. David M. Rodman M.D. | Chief Medical Officer |
Cindy Berejikian | Executive Vice President of Operations |
Sarah Foster | Vice President of Human Resources |
Dr. Robert McKean Ph.D. | Senior Vice President of CMC |
Danielle Bradbury | Senior Vice President of Quality Assurance |
Jeffrey N. Fellows | Senior Vice President of Regulatory Affairs |
Jessica Ibbitson | Senior Vice President of Clinical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 30, 2024 | 8-K | Current Report |
Oct 11, 2024 | 144 | Filing |
Oct 11, 2024 | 144 | Filing |
Sep 25, 2024 | 8-K | Current Report |
Aug 13, 2024 | 10-Q | Quarterly Report |
Aug 13, 2024 | 8-K | Current Report |
Jul 24, 2024 | 144 | Filing |
Jul 16, 2024 | 144 | Filing |
Jul 11, 2024 | 144 | Filing |
Jul 11, 2024 | 144 | Filing |